Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 9/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | OGG1 | O15527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376000 | 0.84 | PGR (0.46) | SCN9APGRCYP17A1GSTP1HPGD | |
| SCHEMBL3374882 | 0.81 | PGR (0.55) | SCN9APGRHPGDHTTHDAC4 | |
| SCHEMBL3378360 | 0.81 | PGR (0.43) | SCN9APGRCYP17A1GSTP1HPGD | |
| SCHEMBL3375581 | 0.78 | HDAC4 (0.41) | SCN9APGRCYP17A1HDAC4 | |
| SCHEMBL13337360 | 0.72 | BRPF1 (0.42) | CYP17A1HDAC4 | |
| SCHEMBL3377038 | 0.70 | ACLY (0.60) | SCN9A | |
| SCHEMBL31621716 | 0.68 | GSTP1 (0.53) | GSTP1 | |
| SCHEMBL3374290 | 0.68 | ACACB (0.45) | CYP17A1 | |
| SCHEMBL3378469 | 0.67 | ACLY (0.51) | SCN9A | |
| SCHEMBL15840918 | 0.67 | SMN1; SMN2 (0.62) | CYP17A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | SCN9A 70/4885PGR 4327/4885CYP17A1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.